BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Xanthus Pharmaceuticals, Inc. Presents Symadex Phase 1 Results At American Society of Clinical Oncology Meeting

  June 5, 2006

   · 

  5 min read
• Drug Development

  Eli Lilly and Company And Alkermes Complete Patient Enrollment For Phase 3 Safety Study For Inhaled Insulin For The Treatment Of Diabetes

  June 5, 2006

   · 

  6 min read
• Drug Development

  Cytogen Corporation Announces Positive Interim Findings From A Phase I Clinical Trial Of QUADRAMET(R) Combination Study In Patients With Relapsed Multiple Myeloma

  June 5, 2006

   · 

  10 min read
• Drug Development

  AstraZeneca PLC Release: New Data Show That Five Years Of Treatment With Arimidex(R) (Anastrozole) Did Not Cause Osteoporosis In Early Breast Cancer Patients With Normal Bone Mineral Density At Outset

  June 5, 2006

   · 

  5 min read
• Drug Development

  Cell Genesys, Inc. And Medarex, Inc. Announce Encouraging Interim Results From A Phase 1 Combination Therapy Trial With GVAX(R) Immunotherapy For Prostate Cancer And Ipilimumab (MDX-010) Antibody

  June 5, 2006

   · 

  10 min read
• Drug Development

  Exelixis, Inc.’ XL880, The First Orally-Available MET Inhibitor In Clinical Development, Continues To Show Promise In A Phase I Trial In Patients With Advanced Solid Tumors

  June 5, 2006

   · 

  7 min read
• Drug Development

  Exelixis, Inc. Release: Encouraging Phase I Trial Results For XL647 In Patients With Advanced Solid Malignancies Presented At American Society of Clinical Oncology

  June 5, 2006

   · 

  6 min read
• Business

  Dr. David A. Evans, Chief Executive Of WellGen, Inc., Passes Away After Sudden Illness

  June 5, 2006

   · 

  2 min read
• Drug Development

  Sanofi-Aventis (France) Release: Results Of A Meta-Analysis Show Benefits Of Taxotere(R) (Docetaxel) Regimens In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

  June 5, 2006

   · 

  6 min read
• Drug Development

  Genta Incorporated Release: Eradication Of Minimal Residual Disease Reported In Patients With Chronic Lymphocytic Leukemia Treated With Chemotherapy Plus Genasense(R)

  June 5, 2006

   · 

  6 min read